Sasa Zivkovic, MD
Neuromuscular Medicine · Guilford, CTNPI 1780650960
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 43.4% of the total. Reporting peaked in 2019 at $17,768 and has fallen 88.7% since, to $2,000 in 2025.
Across 58 payments — averaging $641.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$16K
- Pfizer$8K
- Akcea Therapeutics, Inc.$5K
- AstraZeneca$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- CSL Behring$2K
- plus $1K from 2 others
Across 10 payments — averaging $15,407 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$84K
- Astrazeneca UK Limited$55K
- Pfizer$15K
What the payments were for
- Consulting fees$21,60358%
- Speaking & faculty fees$5,06014%
- Travel & lodging$8,84324%
- Food & beverage$1,6835%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 31 | $16,155 |
| Pfizer | 7 | $8,163 |
| Akcea Therapeutics, Inc. | 12 | $5,026 |
| AstraZeneca | 2 | $2,685 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,288 |
| CSL Behring | 1 | $1,560 |
| Argenx US, Inc. | 2 | $1,183 |
| Sobi, Inc | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 110 | $2,128 |
| Duloxetine Hcl | 17 | $934 |
| Tizanidine Hcl | 59 | $859 |
| Baclofen | 27 | $513 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 34 | $371 |
| Pregabalin | 28 | $296 |
| Nortriptyline Hcl | 21 | $208 |
| Prednisone | 13 | $63 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Guilford
- John TauroNorwich$54K
- Bhaskar RoyNew Haven$17K
- Barry GordonMeriden$3K
- Kevin FeliceNew Britain$2K
- David TinklepaughMystic$2K
- Ylec Cardenas CastilloNew Haven$1K
- Arpad FejosMiddletown$1K
- Bilal HameedNew London$1K
- Zara KhanWestport$1K
- Idaira Aguilar TejedorStratford$864
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.